Small animal positron emission tomography imaging and in vivo studies of atherosclerosis

  title={Small animal positron emission tomography imaging and in vivo studies of atherosclerosis},
  author={Anne Mette Fisker Hag and Rasmus Sejersten Ripa and Sune Folke Pedersen and Rasmus Poul Bodholdt and Andreas Kjaer},
  journal={Clinical Physiology and Functional Imaging},
Atherosclerosis is a growing health challenge globally, and despite our knowledge of the disease has increased over the last couple of decades, many unanswered questions remain. As molecular imaging can be used to visualize, characterize and measure biological processes at the molecular and cellular levels in living systems, this technology represents an opportunity to investigate some of these questions in vivo. In addition, molecular imaging may be translated into clinical use and eventually… Expand
Perspectives on Small Animal Radionuclide Imaging; Considerations and Advances in Atherosclerosis
This review addresses nuclear SPECT and PET imaging in small animals in relation to the atherosclerotic disease process, one of the research topics of interest, and discusses technical considerations that apply to image acquisition, reconstruction, and analysis. Expand
Radiotracer Imaging of Peripheral Vascular Disease
Radiotracer imaging of the lower extremities with techniques such as PET and SPECT can provide a noninvasive quantitative technique for the evaluation of the pathophysiology associated with PVD and may complement clinical indices and other imaging approaches. Expand


The Vascular Biology of Atherosclerosis and Imaging Targets
The imaging of atherosclerosis is reaching beyond anatomy to encompass assessment of aspects of plaque biology related to the pathogenesis and complication of the disease. Expand
Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis
Improved sensitivity; direct correlation of PET signal with an established biomarker (CD68); ability to readily quantify the PET signal, perform whole-body vascular surveys, and spatially localize and follow the trireporter by microscopy; and clinical translatability of the agent given similarities to magnetic resonance imaging probes in clinical trials are established. Expand
Small animal PET in preclinical studies: opportunities and challenges.
  • B. Riemann, K. Schäfers, O. Schober, M. Schäfers
  • Medicine
  • The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
  • 2008
Small animal positron emission tomography has the potential to accelerate and streamline drug and molecular imaging discovery and development by preselection of suitable candidate molecules by employing its significantly improved spatial resolution and quantitative nature. Expand
Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT.
  • A. Chatziioannou
  • Materials Science, Medicine
  • Proceedings of the American Thoracic Society
  • 2005
A brief review of dedicated small animal positron emission tomography and single-photon emission computed tomography introduces the fundamental principles behind these imaging technologies and instrumentation and discusses the limitations in terms of their spatial resolution and sensitivity. Expand
Positron emission tomography tracers for imaging angiogenesis
Because the most intensive work is concentrated on the development of radiolabelled RGD peptides for imaging αvβ3 expression, which has successfully made its way from bench to bedside, these developments are especially emphasized. Expand
Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview.
The experimental and pilot clinical studies reviewed in the present paper represent a fundamental step prior to the evaluation of the efficacy of any selected tracer for the early, non-invasive detection of vulnerable patients. Expand
FDG-PET imaging of atherosclerosis: Do we know what we see?
The initial findings suggest that vascular FDG-PET may in the future find some utility in management of patients with atherosclerosis, but a number of important issues need to be addressed first. Expand
Clinical applications of PET in oncology.
The physics and instrumentation aspects of PET, an analogue of glucose, are described and are being used in diagnosis and follow-up of several malignancies, and the list of articles supporting its use continues to grow. Expand
Small-Animal Molecular Imaging Methods
Given the increasing use of small animals for evaluating new clinical imaging techniques and providing more insight into pathophysiologic phenomena as well as the availability of improved detection systems, scanning protocols, and associated software, the sensitivity and specificity of molecular imaging are increasing. Expand
In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients.
If subsequent natural history studies link increased FDG-PET activity in carotid arteries with clinical events, this noninvasive measure could be used to identify a subset of patients withcarotid atherosclerosis in need of intensified medical therapy orCarotid artery intervention to prevent stroke. Expand